HealthMonday, October 26, 20261 min read

STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

By Adam Feuerstein · Via STAT Health · Published by Everything Blog

In short

The drug, called sacituzumab tirumotecan, or sac-TMT, significantly reduced the risk of death in patients with advanced endometrial cancer, cutting the risk by one-third according to randomized Phase 3 study results presented at a Madrid conference.

Key points

The drug, sac-TMT, is a targeted chemotherapy drug developed by Merck and Kelun-Biotech.: The drug, sac-TMT, is a targeted chemotherapy drug developed by Merck and Kelun-Biotech.
It significantly reduced the risk of death in patients with advanced endometrial cancer,…: It significantly reduced the risk of death in patients with advanced endometrial cancer, cutting the risk by one-third.
This is a common gynecological cancer that has shown survival-extending benefits in studi…: This is a common gynecological cancer that has shown survival-extending benefits in studies conducted by Kelun in China, where it’s approved.

Sources checked by our analysis pipeline: 1

MADRID — A type of targeted chemotherapy developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer, a common gynecological cancer, according to randomized Phase 3 study results presented Monday.

The drug, called sacituzumab tirumotecan, or sac-TMT, has already shown survival-extending benefits for patients across multiple cancer types in studies conducted by Kelun in China, where it’s approved.

Merck is conducting 18 global Phase 3 studies of sac-TMT, including 10 studies in women’s cancers, to support approvals in the U.S., Europe, and elsewhere outside China. The drug plays a crucial role in Merck’s efforts to replace revenue that will be lost when Keytruda, its blockbuster immunotherapy, loses patent protection in 2028.

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Original source: www.statnews.com

AI Analysis

Tone

Positive

In short

Key Points

The drug, sac-TMT, is a targeted chemotherapy drug developed by Merck and Kelun-Biotech.: The drug, sac-TMT, is a targeted chemotherapy drug developed by Merck and Kelun-Biotech.
It significantly reduced the risk of death in patients with advanced endometrial cancer,…: It significantly reduced the risk of death in patients with advanced endometrial cancer, cutting the risk by one-third.
This is a common gynecological cancer that has shown survival-extending benefits in studi…: This is a common gynecological cancer that has shown survival-extending benefits in studies conducted by Kelun in China, where it’s approved.

Topics

Health

Was this summary useful?

AI Analysis

Tone

Positive

In short

Key Points

The drug, sac-TMT, is a targeted chemotherapy drug developed by Merck and Kelun-Biotech.: The drug, sac-TMT, is a targeted chemotherapy drug developed by Merck and Kelun-Biotech.
It significantly reduced the risk of death in patients with advanced endometrial cancer,…: It significantly reduced the risk of death in patients with advanced endometrial cancer, cutting the risk by one-third.
This is a common gynecological cancer that has shown survival-extending benefits in studi…: This is a common gynecological cancer that has shown survival-extending benefits in studies conducted by Kelun in China, where it’s approved.

Topics

Health

Was this summary useful?

STAT+: GSK sees its return to cancer starting to pay off
GSK, a pharmaceutical giant, is experiencing a resurgence in its cancer treatment efforts, with a drug receiving approval for another tumor type, and the company unveiling data from a global study of a promising next-generation chemotherapy. Additionally, a medicine licensed by GSK has gained attention in a presidential session at a major oncology conference, and the company is awaiting another expected approval for a new lung cancer drug in the coming weeks. This positive run for GSK in the oncology field is a te…
1 min read
Toddler Dies As Mother Falls From Terrace While Trying To Escape Monkeys In UP
A toddler died after falling from a terrace while their mother attempted to escape from monkeys in Uttar Pradesh, India. The child was rushed to the hospital but later succumbed to his injuries.
1 min read
STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more
A patient died after receiving Bristol’s investigational CAR-T therapy, and Roche’s lung cancer drug showed promising results in a late-stage study. These developments highlight safety concerns and potential breakthroughs in the rapidly evolving field of cancer treatment.
1 min read

STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

In short

Key points

More in Health